Tags

Type your tag names separated by a space and hit enter

Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapy.
Br J Pharmacol. 2020 11; 177(21):4931-4941.BJ

Abstract

The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H2 S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H2 S-releasing agents have been developed as potential therapeutic tools for diseases related with impaired H2 S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H2 S in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some H2 S-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H2 S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H2 S levels and severity of COVID-19. Therefore, repurposing of H2 S-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Department of Pharmacy, University of Pisa, Pisa, Italy.Department of Pharmacy, University of Pisa, Pisa, Italy.Department of Science, University of Basilicata, Potenza, Italy.Department of Pharmacy, University of Pisa, Pisa, Italy.Sulfagenix, Inc., Tucson, Arizona, USA.Department of Science, University of Basilicata, Potenza, Italy.Sulfagenix, Inc., Tucson, Arizona, USA.Department of Pharmacy, University of Pisa, Pisa, Italy.Department of Pharmacy, University of Pisa, Pisa, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32783196

Citation

Citi, Valentina, et al. "Anti-inflammatory and Antiviral Roles of Hydrogen Sulfide: Rationale for Considering H2 S Donors in COVID-19 Therapy." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4931-4941.
Citi V, Martelli A, Brancaleone V, et al. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapy. Br J Pharmacol. 2020;177(21):4931-4941.
Citi, V., Martelli, A., Brancaleone, V., Brogi, S., Gojon, G., Montanaro, R., Morales, G., Testai, L., & Calderone, V. (2020). Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapy. British Journal of Pharmacology, 177(21), 4931-4941. https://doi.org/10.1111/bph.15230
Citi V, et al. Anti-inflammatory and Antiviral Roles of Hydrogen Sulfide: Rationale for Considering H2 S Donors in COVID-19 Therapy. Br J Pharmacol. 2020;177(21):4931-4941. PubMed PMID: 32783196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapy. AU - Citi,Valentina, AU - Martelli,Alma, AU - Brancaleone,Vincenzo, AU - Brogi,Simone, AU - Gojon,Gabriel, AU - Montanaro,Rosangela, AU - Morales,Guillermo, AU - Testai,Lara, AU - Calderone,Vincenzo, Y1 - 2020/08/26/ PY - 2020/07/01/received PY - 2020/07/19/revised PY - 2020/08/02/accepted PY - 2020/8/13/pubmed PY - 2020/10/28/medline PY - 2020/8/13/entrez KW - COVID-1 KW - H2S-donor KW - SARS-CoV-2 KW - drug repurposing KW - hydrogen sulfide SP - 4931 EP - 4941 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H2 S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H2 S-releasing agents have been developed as potential therapeutic tools for diseases related with impaired H2 S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H2 S in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some H2 S-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H2 S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H2 S levels and severity of COVID-19. Therefore, repurposing of H2 S-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32783196/Anti_inflammatory_and_antiviral_roles_of_hydrogen_sulfide:_Rationale_for_considering_H2_S_donors_in_COVID_19_therapy_ L2 - https://doi.org/10.1111/bph.15230 DB - PRIME DP - Unbound Medicine ER -